*Fewer potentially problematic patent settlements in EU. LONDON, Dec 9- A crackdown by regulators on deals between drugmakers that unfairly delay the launch of cheap generic medicines appears to be working, with data on Monday showing firms in Europe are avoiding settlements involving pay-offs.» Read More
Amylin Pharmaceuticals has felt the pressure of late since Merck released a diabetes drug to rival its own Byetta. And there’s no relief in sight with Novartis not far behind in getting approval for its Galvus treatment. CNBC’s Mike Huckman spoke with Amylin CEO Ginger Graham about how the competition is affecting the company.
The U.S. Supreme Court sided with MedImmune and reinstated the company's lawsuit challenging the validity of a key Genentech patent.
As we've said--CNBC pharmaceuticals reporter Mike Huckman is at the 25th Annual JPMorgan Healthcare Conference in San Francisco this week. This morning on “Squawk on the Street” he got a chance to talk to Celgene Chairman and CEO Sol Barer. Barer’s company is up 365% over the past three years and has a cancer-fighting drug he says has “multibillion-dollar potential.”
Google, which seems to surpass the competition in any market it enters, is now leading yet another category – Fortune‘s “100 Best Companies To Work For.” Andrew Serwer, editor at large for the magazine, spoke to Joe Kernen on “Squawk Box” this morning about why the internet bellwether’s employees are so happy.
BioCryst Pharmaceuticals has won a $102.6 million government contract for advanced development of its influenza antiviral drug, peramivir.
CNBC’s Bob O’Brien talked with Michelle Caruso-Cabrera about his stock winners and losers for the day so far. Some poor December retail sales numbers and less-than-stellar economic data caused sharp losses in the Dow, but a semiconductor rally is sparking a comeback. O’Brien says Intel is leading the pack.
As we've been writing--CNBC pharmaceuticals reporter Mike Huckman has been reporting from Gaithersburg, Md--where the U.S. Food and Drug Administration has convened a panel to decide the fate of drug-coated stents. Johnson & Johnson and Boston Scientific – the two major producers of stents – have been eagerly awaiting a decision.
Pfizer stock is down 13% so far today on news that development of its Lipitor successor – torceptrapib – has been halted. Analysts have downgraded the stock and cut price targets as a result. Barbara Ryan – managing director and senior analyst at Deutsche Bank – disagrees though. She appeared on “Morning Call” to say that the dip in price today is a buy-in opportunity.